Tumor Metastatic Model Development Service

Tumor Metastatic Model Development Service

Metastasis is the process by which cancer cells migrate through lymph or blood vessels, leading to the formation of new tumors in distant organs. It is the primary cause of death in the majority of bladder cancer cases. At Alfa Cytology, we specialize in providing our clients with tumor metastatic models specifically designed for bladder cancer research.

Introduction to Metastatic Bladder Cancer

In muscle-invasive bladder cancer, approximately 25 percent will either have metastases at the time of diagnosis or develop metastases later on. The most common sites of metastasis in bladder cancer include the lymph nodes, lungs, liver, and bones. Local infiltration and peripheral lymph node metastasis are more frequently observed in bladder cancer metastasis, while distant metastasis occurs less frequently.

 Fig 1. Metastatic Bladder Cancer.

Although metastasis is the cause of most bladder cancer-related deaths, the mechanisms of metastatic disease are not yet fully understood, in part due to the lack of preclinical in vivo models. The development of advanced preclinical models of metastasis will help us understand bladder cancer progression and develop new therapies for metastatic bladder cancer.

Our Services

Alfa Cytology, a leading provider of preclinical contract research organization (CRO) services, specializes in tumor metastatic model development for bladder cancer. Our services include but are not limited to:

Development of Orthotopic Mouse Models Development of Patient-Derived Xenografts (PDX) Development of Genetically Engineered Mouse Models (GEMMs)

 Fig 2. Development of Orthotopic Mouse Models.

Fig 3. Development of Patient-Derived Xenografts (PDX).

Fig 4. Development of Genetically Engineered Mouse Models (GEMMs).

By implanting bladder cancer cells directly into the bladder wall of mice, we recreate the complex interactions between tumor cells and the bladder microenvironment. Our PDX service involves the transplantation of patient-derived tumor tissue or cells into immunocompromised mice. This enables the preservation of the genetic and phenotypic characteristics of the original patient tumor. We specialize in the development of GEMMs for bladder cancer research, where specific mutations or alterations associated with bladder cancer are introduced into mice.

Our Services Will Help You Achieve the Goals as Follows:

Models Functions
Orthotopic Mouse Models
  • Relevance to the human microenvironment, closely mimicking the characteristics of human bladder tumors.
  • Ability to study local invasion, intravesical spread, and distant metastasis observed in human.
  • Investigation of metastatic processes and identification of potential biomarkers.
PDX
  • Preservation of genetic and phenotypic characteristics of the original tumor.
  • Investigation of tumor heterogeneity and individualized therapy responses.
  • Identification of predictive biomarkers and evaluation of therapeutic efficacy.
Genetically Engineered Mouse Models (GEMMs)
  • Study of specific genetic alterations associated with bladder cancer.
  • Investigation of molecular mechanisms underlying bladder cancer metastasis.
  • Analysis of the interplay between genetic alterations, tumor microenvironment, and metastatic progression.
  • Insight into the spontaneous development of bladder tumors and metastases.

Contact Us

At Alfa Cytology, we are committed to providing comprehensive preclinical CRO services in the field of bladder cancer research. Our tumor metastatic model development service offers advanced orthotopic mouse models, PDX, and genetically engineered mouse models tailored to the study of bladder cancer metastasis. Our team of experts is dedicated to accelerating your research projects, enabling early diagnosis, and developing effective therapeutics strategies for bladder cancer. If you have any needs, please contact us.

Reference

  1. Tatum, J.L., Kalen, J.D., and et al. A spontaneously metastatic model of bladder cancer: imaging characterization. J Transl Med. 2019, 17, 425.
For research use only. Not intended for any clinical use.
Related Services
About Us

Alfa Cytology is dedicated to drug development and preclinical services for bladder cancer.

Contact Us
  • twitter
Copyright © Alfa Cytology. All Rights Reserved.
Top